变异组织学肌层浸润性膀胱癌新辅助化疗的病理降期与生存结局
这项基于美国国家癌症数据库2004–2017年的回顾性研究纳入31,218例接受根治性膀胱切除术的非转移性肌层浸润性膀胱癌患者,评估新辅助化疗与病理降期及总生存的关联。结果显示新辅助化疗在所有组织学亚组中均与病理降期至pT0N0相关,并与尿路上皮癌、肉瘤样变异型尿路上皮癌和神经内分泌癌的总生存改善相关。
要点
- 新辅助化疗在所有组织学亚组中均与病理降期至pT0N0显著相关。
- 总生存获益见于尿路上皮癌、肉瘤样变异型尿路上皮癌和神经内分泌癌。
- 其他变异组织学(微乳头、鳞癌、腺癌)的生存关联未报告。
核心结论
- 新辅助化疗与所有肌层浸润性膀胱癌组织学变异型的病理降期相关。
- 新辅助化疗与尿路上皮癌、肉瘤样变异型尿路上皮癌和神经内分泌癌的总生存改善相关。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库2004–2017年。
- 纳入31,218例非转移性肌层浸润性膀胱癌接受根治性膀胱切除术的患者。
- 按组织学亚组和新辅助化疗接受与否分层,病理降期定义为pT0N0或pT≤1N0。
临床怎么用
- 对于变异组织学肌层浸润性膀胱癌,新辅助化疗可考虑用于争取病理降期。
- 尿路上皮癌、肉瘤样变异型尿路上皮癌和神经内分泌癌患者可能从新辅助化疗中获得总生存获益。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 未报告微乳头状变异型尿路上皮癌、鳞状细胞癌和腺癌的总生存关联结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with muscle invasive bladder cancer (MIBC) of variant histology have a poor prognosis. It is unclear if neoadjuvant chemotherapy prior to radical cystectomy is associated with pathological downstaging or improved overall survival (OS) for patients with variant histology. Our objective was to assess for associations between receipt of neoadjuvant chemotherapy, pathological downstaging and OS for patients with variant histology MIBC. MATERIALS AND METHODS: Patients were identified in the National Cancer Database from 2004 to 2017 with MIBC, without metastases, who underwent radical cystectomy. Patients were stratified by histological subgroup, and receipt or nonreceipt of neoadjuvant chemotherapy. Pathological downstaging was defined as pT0N0 or pT ≤1N0, and OS from the time of diagnosis to date of death or censoring at last followup. Multivariable logistic regression analysis determined associations between neoadjuvant chemotherapy and pathological downstaging. Multivariable Cox regression analysis determined associations between neoadjuvant chemotherapy and OS. RESULTS: A total of 31,218 patients were included in the final study population (urothelial carcinoma [UC]: 27,779; sarcomatoid UC: 501; micropapillary UC: 418; squamous cell carcinoma: 1,141; neuroendocrine carcinoma: 629; adenocarcinoma: 750). Neoadjuvant chemotherapy was associated with pathological downstaging to pT0N0 in all histological subgroups (UC: OR 5.1 [4.6-5.6]; sarcomatoid UC: OR 13.8 [5.5-39.0]; micropapillary UC: OR 9.7 [2.8-46.8]; squamous cell carcinoma: OR 7.4 [2.1-24.5]; neuroendocrine: OR 4.7 [2.6-9.2]; adenocarcinoma: OR 23.3 [8.0-74.2]). Neoadjuvant chemotherapy was associated with improved OS for UC (HR 0.8 [0.77-0.84]), sarcomatoid UC (HR 0.64 [0.44-0.91]) and neuroendocrine carcinoma (HR 0.55 [0.43-0.70]). CONCLUSIONS: Neoadjuvant chemotherapy was associated with pathological downstaging for all MIBC histological variants, with improved OS for patients with UC, sarcomatoid variant UC and neuroendocrine carcinoma.
引用
- Chakiryan NH, Jiang DD, Gillis KA, et al. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021. PMID: 34032503. doi:10.1097/JU.0000000000001855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。